Comparison · NCT00297882-sae
1 Artemether-Lumefantine (AL) vs 2 Amodiaquine-Artesunate (AQ-AS): serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. 1 Artemether-Lumefantine (AL) vs 2 Amodiaquine-Artesunate (AQ-AS): serious adverse events. Trial comparisons, record NCT00297882-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT00297882-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.0294 | 0.0135 | 0.0627 | wilson | |
| Risk in group 2 | 0.0049 | 0.00167 | 0.0143 | wilson | |
| Risk difference, group 1 minus group 2 | 0.0245 | 0.00607 | 0.0579 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 6 | 1.51 | 23.8 | log | |
| Odds ratio, group 1 over group 2 | 6.15 | 1.52 | 24.8 | log | |
| Number needed to harm, for one more participant with a serious adverse event on 1 Artemether-Lumefantine (AL) than on 2 Amodiaquine-Artesunate (AQ-AS) | 40.8 | 17.3 | 165 | from the risk difference interval |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | 1 Artemether-Lumefantine (AL) | Study group 1. Subjects in this group received treatment with Artemether-Lumefantrine. Children received 2 mg/kg Artemether and 12 mg/kg Lumefrantrine with milk twice daily (or every 12 hours for 3 days. | 6 | 204 | EG000 |
| Group 2 | 2 Amodiaquine-Artesunate (AQ-AS) | Study group 2. Subjects in this group received treatment with Amodiaquine-Artesunate. Children received a co-administered combination of 30 mg/kg Amodiaquine (AQ) plus 4 mg/kg Artesunate (AS) daily for 3 days. | 3 | 612 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
- 28 days following treatment.
Source ClinicalTrials.gov
Trial
- Title
- Artemisinin-Based Combination Therapy: Clinical Trials in Cameroon
- NCT number
- NCT00297882
- Phases
- PHASE3
- Conditions
- Malaria
- Interventions
- 1. Artemether-Lumefantrine (AL), 2. Amodiaquine-Artesunate (AQ-AS)
- Lead sponsor
- London School of Hygiene and Tropical Medicine
- Results first posted
- 2021-06-08
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT00297882?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT00297882-sae